Home » NOVARTIS SEALS RESEARCH ALLIANCE WITH ALNYLAM
NOVARTIS SEALS RESEARCH ALLIANCE WITH ALNYLAM
Drugmaker Novartis unveiled a research alliance with U.S.-based Alnylam Pharmaceuticals worth up to $700 million and aimed at a hot field of gene therapy called RNA interference, or RNAi. The collaboration is designed to produce new treatments using RNAi therapy -- used to "silence" disease-causing genes -- for numerous ailments and is especially promising for diseases that evade traditional treatments, Novartis said in a statement. Analysts welcomed the deal as making strategic sense for the Basel-based drugmaker which has spent billions of dollars so far this year to bolster the various parts of its business.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May